TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Shaughnessy, John D.; Yiming Zhou; Haessler, Jeff; van Rhee, Frits; Anaissie, Elias; Nair, Bijay; Waheed, Sarah; Alsayed, Yazan; Epstein, Joshua; Crowley, John; Barlogie, Bart; British Journal of Haematology, 2009, vol. 147, issue 3, p 347, ISSN 00071048. ISBN 13652141.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef